Device/Diagnostics Quarterly Deal Statistics, Q1 2015

Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.

Device financing reached $934 million during 2015's first quarter, a slight increase over Q4's $902 million. (See Exhibit 1.) Representing 37% of the financing total, follow-on public offerings drove most of the quarter's fundraising with $343 million, a significant increase over Q4's sole $12 million FOPO by implantable orthopedic device and biomaterials company Amedica Corp.[See Deal]

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By 

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By 

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Deals In Depth: February 2025

 
• By 

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Deals Shaping The Industry, February 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during February 2025. Data courtesy of Biomedtracker.

More from In Vivo

Building The Worm Atlas For I&I Breakthroughs

 
• By 

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Reforming The Rx Rulers: A New Script For PBMs

 
• By 

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

 
• By 

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.